News
MODULATING DNA DAMAGE RESPONSES TO CURE CANCER
Contact Us
Breakpoint Therapeutics GmbH
Essener Bogen 7
22419 Hamburg (Germany)
Telefon: +49 40 56081 180
E-mail: info@breakpointtx.com
Impressum
Registergericht: Hamburg
Registernummer: HRB 155717
Umsatzsteuer-Identifikationsnummer: DE 324 797 830
Geschäftsführer / Managing Directors
Dr. Daniel Speidel and Jonathan Hollick
Breakpoint To Present At BIO International Convention 2023
Breakpoint’s Managing Director Daniel Speidel will present a company overview at BIO International Convention in Boston on June 7, 2023. 12:15pm, Session Room 104A.
Breakpoint To Present At DDR Inhibitors Summit, 2023
Breakpoint’s Managing Director and Head of Research Jon Hollick will give a talk entitled “Next Generation DDR/Synthetic Lethality Targets: Mining DNA Metabolism for Gold” at the DDR Inhibitors Summit in Boston, 24-26 January 2023.
BVF Partners L.P. Joins Breakpoint’s Investor Syndicate
Biotechnology Value Fund (BVF Partners), a San Francisco-based private investment partnership, has contributed capital in an extension of Breakpoint Therapeutics’ last funding round. Gorjan Hrustanovic, Managing Director at BVF Partners, will join Breakpoint’s Advisory Board as an Observer.